Cara Therapeutics | CARA - Betriebsergebnis

Aktienkurs
2.90
Täglich Wechseln
-0.06 -2.03%
Monatlich
-23.28%
Jährlich
-80.27%
Q2 Prognose
2.82




Betriebsergebnis Veränderung Datum
Acadia Pharmaceuticals USD 17.39M 18.36M 2025-12
Alterity Therapeutics Limited AUD -8.07M 302.4K 2025-12
Assertio Holdings USD -3.05M 569K 2024-09
Cara Therapeutics USD -5.94M 3.55M 2025-09
Cassava Sciences USD -13.55M 1.69M 2025-12
Chugai Pharma JPY 169.01B 12.52B 2025-12
Cipla INR 9.77B 6.21B 2025-12
Clal Biotechnology ILS -1.74M 7.46M 2022-12
Compugen USD 56.04M 63.93M 2025-12
CSL USD 2.64B 1.97B 2025-12
Grifols EUR 320.55M 91.01M 2025-12
Halozyme Therapeutics USD -88.41M 306.33M 2025-12
J&J USD 5.59B 1.81B 2025-12
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
Pacira USD 3.19M 9.96M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
RedHill Biopharma USD -4.22M 1.8M 2024-06
Supernus Pharmaceuticals USD 13.82M 74.01M 2025-12
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12